Axsome Therapeutics, Inc. Revenue From Contract With Customer Excluding Assessed Tax

Quick Answer

Axsome Therapeutics, Inc. reported Revenue From Contract With Customer Excluding Assessed Tax of $638.50 million for the year ending 2025.

  • Axsome Therapeutics, Inc. showed an increase of +65.5% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
  • This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
  • XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 4 years of available data (2022 to 2025), Axsome Therapeutics, Inc.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 1,176.0%.
  • Historical annual values: Fiscal year 2025: $638.50 million | Fiscal year 2024: $385.69 million | Fiscal year 2023: $270.60 million | Fiscal year 2022: $50.04 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: